BlossomHill Therapeutics, Inc. BLSM
14.69 USD +1.04 (+7.62%)
As ofNov 17, 2026, 12:01 PM EST
13.09 Day range 14.71
11.02 52-week range 27.99
- YTD
- -8.19%
- 1 year
- -8.19%
News
globenewswire.com BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date Announced SOLARA-2,…benzinga.com BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027
benzinga.com BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
